



LKT Laboratories, Inc.

Dacomitinib Monohydrate

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information


Product ID D0006
CAS No. 1042385-75-0
Chemical Name (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide;hydrate
Synonym PF-00299804

Formula C₂₄H₂₅ClFN₅O₂ • H₂O
Formula Wt. 487.95
Melting Point
Purity ≥99%
Solubility Soluble in water (<1 mg/ml at 25 °C), ethanol (<1 mg/ml at 25 °C), DMSO (19 mg/ml at 25 °C), and 1% DMSO/30% polyethylene glycol/1% Tween 80, pH 9 (10 mg/ml at 25 °C).

Store Temp -20 °C

Ship Temp Ambient

Description Dacomitinib is an ATP-competitive, irreversible pan-erbB receptor (EGFR) inhibitor that shows anticancer chemotherapeutic activity in models of squamous cell carcinoma, ovarian carcinoma, and non-small-cell lung cancer (NSCLC). Dacomitinib covalently modifies cytosine residues in the catalytic domain of this kinase, preventing phosphorylation of downstream targets such as Akt, and ERK, resulting in cell cycle arrest at the G0/G1 phase and induction of apoptosis. This compound also inhibits mutant EGF receptors in drug-resistant in vivo tumor models.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
D0006	1 mg	\$86.80
D0006	5 mg	\$167.90
D0006	25 mg	\$445.70

References Kalous O, Conklin D, Desai AJ, et al. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. *Mol Cancer Ther.* 2012 Sep;11(9):1978-87. PMID: 22761403.

Gonzales AJ, Hook KE, Althaus IW, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. *Mol Cancer Ther.* 2008 Jul;7(7):1880-9. PMID: 18606718.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.